for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adaptimmune Therapeutics PLC - ADR

ADAP.OQ

Latest Trade

8.01USD

Change

0.15(+1.91%)

Volume

191,075

Today's Range

7.66

 - 

8.29

52 Week Range

0.71

 - 

13.39

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.86
Open
7.90
Volume
191,075
3M AVG Volume
67.99
Today's High
8.29
Today's Low
7.66
52 Week High
13.39
52 Week Low
0.71
Shares Out (MIL)
927.97
Market Cap (MIL)
1,215.25
Forward P/E
-8.29
Dividend (Yield %)
--

Latest Developments

More

Adaptimmune Reports Q2 Loss Per Share $0.04

Adaptimmune Proposes Public Offering Of American Depositary Shares

Spear T-Cells Targeting Mage-A4 Demonstrate New Responses In Esophagogastric Junction (Egj), Lung, And Head And Neck Cancers

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adaptimmune Therapeutics PLC - ADR

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company’s product pipeline includes ADP-A2M4, ADP-A2M4CD8, ADP-A2AFP and ADP-A2M10. Its ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types.

Industry

Biotechnology & Drugs

Contact Info

60 Jubilee Avenue

OX14 4RX

United Kingdom

+44.1235.430000

https://www.adaptimmune.com/

Executive Leadership

David M. Mott

Non-Executive Independent Chairman of the Board

Adrian Rawcliffe

Chief Executive Officer, Director

Gavin Hilary James Wood

Chief Financial Officer

William C. Bertrand

Chief Operating Officer

Elliot Norry

Senior Vice President, Chief Medical Officer

Key Stats

2.38 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.1K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.780

2018

-0.960

2019

-1.320

2020(E)

-0.911
Price To Earnings (TTM)
--
Price To Sales (TTM)
545.44
Price To Book (MRQ)
2.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-37.00
Return on Equity (TTM)
-33.71

Latest News

Latest News

BRIEF-Adaptimmune Therapeutics PLC Prices Public Offering Of American Depositary Shares

* ADAPTIMMUNE THERAPEUTICS PLC PRICES PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

BRIEF-Adaptimmune Proposes Public Offering Of American Depositary Shares

* ADAPTIMMUNE THERAPEUTICS PLC PROPOSES PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

BRIEF-Spear T-Cells Targeting Mage-A4 Demonstrate New Responses In Esophagogastric Junction (Egj), Lung, And Head And Neck Cancers

* SPEAR T-CELLS TARGETING MAGE-A4 DEMONSTRATE NEW RESPONSES IN ESOPHAGOGASTRIC JUNCTION (EGJ), LUNG, AND HEAD AND NECK CANCERS – LATE STAGE DEVELOPMENT INITIATED IN EGJ CANCER

BRIEF-Adaptimmune Therapeutics Reports Qtrly Loss Per Share $0.04

* ADAPTIMMUNE THERAPEUTICS PLC SEES AS OF MARCH 31, 2020, ADAPTIMMUNE HAD CASH AND CASH EQUIVALENTS OF $86.4 MILLION

BRIEF-Adaptimmune Therapeutics To Rely On SEC Order To Delay Filing Of Its Quarterly Report On Form 10-Q

* ADAPTIMMUNE THERAPEUTICS PLC - WILL BE RELYING ON SEC ORDER TO DELAY FILING OF ITS QUARTERLY REPORT ON FORM 10-Q FOR THREE MONTHS ENDED MARCH 31, 2020 Source : (https://bit.ly/2xmcdKc) Further company coverage:

BRIEF-EMA Committee for Orphan Medicinal Products adopts positive opinion for Orphan Drug Designation for ADP-A2M4 -Adaptimmune Therapeutics

* POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION FOR ADP-A2M4 IN THE EUROPEAN UNION FOR THE TREATMENT OF SOFT TISSUE SARCOMA FROM EMA' COMMITTEE OF ORPHAN MEDICINAL PRODUCTS Source text for Eikon: Further company coverage:

BRIEF-Adaptimmune Reports Qtrly Loss Per Share $0.05

* ADAPTIMMUNE REPORTS FOURTH QUARTER / FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-Adaptimmune Announces Appointment Of Gavin Wood As CFO

* ADAPTIMMUNE ANNOUNCES APPOINTMENT OF GAVIN WOOD AS CHIEF FINANCIAL OFFICER

BRIEF-Adaptimmune Reports Q1 Loss Per Share $0.04

* ADAPTIMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-Adaptimmune Therapeutics Reports Quarterly Loss Per Ordinary Share Of $0.05

* ADAPTIMMUNE REPORTS FOURTH QUARTER / FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-Adaptimmune Announces Responses In Second Solid Tumor Indication

* ADAPTIMMUNE ANNOUNCES RESPONSES IN SECOND SOLID TUMOR INDICATION WITH NY-ESO SPEAR T-CELLS

BRIEF-Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK

* ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING

BRIEF-Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells

* ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE

BRIEF-Adaptimmune Therapeutics Q3 loss per share $0.00

* Adaptimmune reports third quarter 2017 financial results and business updates

BRIEF-Matrix Capital reports 12.9 pct passive stake in Adaptimmune Therapeutics

* Matrix Capital Management Company Lp reports 12.9 percent passive stake in Adaptimmune Therapeutics Plc as of August 31, 2017 - SEC filing Source text: (http://bit.ly/2wSEc1U)

GSK bets on pioneering cancer therapy with Adaptimmune deal

GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.

BRIEF-GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO

* Adaptimmune Therapeutics Plc - GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up